from BIOMERIEUX (EPA:BIM)
bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Marcy-l’Étoile (France), April 9th, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of BIOFIRE® SPOTFIRE® for pharmaceutical industries, where this innovative molecular testing system is designed to transform quality control. Building on the proven success of the BIOFIRE® FILMARRAY® platform, already adopted by leading global pharmaceutical companies, BIOFIRE® SPOTFIRE® introduces a simple, small and smart approach to mycoplasma detection, helping biopharmaceutical manufacturers strengthen quality control, accelerate decision-making, and protect patients.
Mycoplasma contamination in pharmaceutical production processes can compromise batch quality, cause significant delays and costs, and ultimately impact patient access to life-saving therapies. Mycoplasmas represent a major and often underestimated threat, capable of inducing profound cellular alterations. Rapid, reliable, and compliant detection of mycoplasmas is therefore essential to help secure bioprocess integrity, prevent cross-contamination risks, and meet regulatory requirements for cell and gene therapies, vaccines, and biologics.
By delivering robust results in less than 1 hour, BIOFIRE® SPOTFIRE® improves operational efficiency and safeguards manufacturing processes. Its automated workflows, intuitive touchscreen interface and integrated barcode scanning minimize manual steps, reduce human error, and help ensure secure, traceable data - enabling faster decisions and shorter production timelines. Stackable modules save benchtop space and provide scalable capacity to meet evolving manufacturing needs.
Compatible with the existing BIOFIRE® Mycoplasma panel, BIOFIRE® SPOTFIRE® ensures continuity for existing users while elevating solution performance and regulatory compliance. Its design reflects bioMérieux’s commitment to innovation, reliability, and data integrity, helping manufacturers anticipate emerging risks, comply with regulatory requirements, and improve operational indicators.
“BIOFIRE® SPOTFIRE® is more than an instrument: it’s a strategic solution for pharmaceutical manufacturers seeking efficiency, compliance, and peace of mind. By combining speed, simplicity, and robust data integrity, we empower our customers to make faster decisions, minimize downtime, and maintain the highest standards of quality - ultimately benefiting patients worldwide.” stated Yasha Mitrotti, Executive Vice President, Industrial Applications, bioMérieux.
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
CONTACTS
INVESTORS RELATIONS
bioMérieux
Aymeric Fichet
Tel: +33 (0)4 78 87 20 00
investor.relations@biomerieux.com
MEDIA RELATIONS
Corporate
Romain Duchez
Tel: +33 (0)4 78 87 20 00
media@biomerieux.com
United States
Todd Siesky
Tel: +1 919.791.5822
todd.siesky@biomerieux.com
France
Isabelle de Segonzac (Image 7)
Tel: +33 (0)1 53 70 74 85
lheilbronn@image7.fr